(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive…
Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent…
Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed…